Roche: FDA Approves Tecentriq With Fluoropyrimidine And Oxaliplatin For Adjuvant Treatment Of A Certain Type Of Stage III Colon Cancer

Tecentriq Plus Chemotherapy Reduces Risk Of Recurrence Or Death By 50% In Phase III ATOMIC Study